Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | CREBBP | Q92793 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Altretamine SCHEMBL4206 | 1.00 | LMNA (1.00) | LMNACYP1A2THRBBLMCREBBP | |
| Altretamine SCHEMBL11746235 | 0.96 | LMNA (0.92) | LMNACYP1A2THRBBLMCREBBP | |
| Altretamine SCHEMBL29131538 | 0.96 | LMNA (0.92) | LMNACYP1A2THRBBLMCREBBP | |
| Altretamine SCHEMBL20770606 | 0.92 | LMNA (0.85) | LMNACYP1A2THRBBLMCREBBP | |
| Altretamine SCHEMBL28400006 | 0.89 | LMNA (0.79) | LMNACYP1A2THRBBLMCREBBP | |
| Altretamine SCHEMBL21612149 | 0.89 | LMNA (0.79) | LMNACYP1A2THRBBLMCREBBP | |
| SCHEMBL12705714 | 0.86 | LMNA (0.73) | LMNACYP1A2THRBBLMCREBBP | |
| SCHEMBL18649270 | 0.83 | LMNA (0.69) | LMNACYP1A2THRBBLMCREBBP | |
| SCHEMBL10976419 | 0.83 | LMNA (0.69) | LMNACYP1A2THRBBLMCREBBP | |
| Altretamine SCHEMBL13287523 | 0.83 | LMNA (0.69) | LMNACYP1A2THRBBLMCREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023049798-A1 | HDAC3 INHIBITORS FOR THE TREATMENT OF LANGERHANS CELL HISTIOCYTOSIS AND LANGERHANS CELL SARCOMA | HENRY FORD HEALTH SYSTEM (US) | 2023-03-30 | — | — | WO | claimed |
| WO-2021110085-A1 | METHOD FOR ASSOCIATING WITH EXPRESSION LEVEL OF AKR1C3 ENZYME VIA CONTENT OF PROSTAGLANDIN, AND USE OF SCREENING FOR DRUG ADMINISTRATION | 深圳艾欣达伟医药科技有限公司 | 2021-06-10 | — | — | WO | claimed |
| WO-2021083310-A1 | ANTI-CANCER COMPOUNDS ACTING AS NON-PGP SUBSTRATE | 深圳艾欣达伟医药科技有限公司 | 2021-05-06 | — | — | WO | claimed |
| US-20240207202-A1 | COMBINATION THERAPIES TARGETING MITOCHONDRIAL BIOGENESIS FOR CANCER THERAPY | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY | 2024-06-27 | — | — | US | disclosed |
| EP-3331558-B1 | COMBINATION THERAPIES TARGETING MITOCHONDRIAL BIOGENESIS FOR CANCER THERAPY | WISTAR INST (US) | 2024-05-15 | — | — | EP | disclosed |
| US-20240092856-A1 | COMBINATION THERAPY OF PD-1-TARGETED IL-2 VARIANT IMMUNOCONJUGATES AND FAP/4-1BB BINDING MOLECULES | HOFFMANN-LA ROCHE INC. (US) | 2024-03-21 | — | — | US | disclosed |
| US-20230181489-A1 | COMBINATION THERAPIES TARGETING MITOCHONDRIAL BIOGENESIS FOR CANCER THERAPY | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY | 2023-06-15 | — | — | US | disclosed |
| US-20230158146-A1 | HSP70 Inhibitors and Methods of Using Same | THE WISTAR INST (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230146903-A1 | CXCR5 Antagonists and Methods of Treating Diseases or Disorders Using Same | YALE UNIVERSITY | 2023-05-11 | — | — | US | disclosed |
| WO-2023049798-A1 | HDAC3 INHIBITORS FOR THE TREATMENT OF LANGERHANS CELL HISTIOCYTOSIS AND LANGERHANS CELL SARCOMA | HENRY FORD HEALTH SYSTEM (US) | 2023-03-30 | — | — | WO | disclosed |
| US-20220213014-A1 | CRYSTALLINE POLYMORPHS OF 1,6-DIBROMO-1,6-DIDEOXY-DULCITOL | Eleison Pharmaceuticals LLC (US) | 2022-07-07 | — | — | US | disclosed |
| US-20170049790-A1 | COMBINATION THERAPIES TARGETING MITOCHONDRIA FOR CANCER THERAPY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-02-23 | — | — | US | disclosed |
| WO-2017024207-A1 | COMBINATION THERAPIES TARGETING MITOCHONDRIAL BIOGENESIS FOR CANCER THERAPY | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2017-02-09 | — | — | WO | disclosed |
| US-20170020964-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF METASTATIC AND REFRACTORY CANCERS AND TUMORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-01-26 | — | — | US | disclosed |
| US-20170014434-A1 | Small Molecule HSP70 Inhibitors | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2017-01-19 | — | — | US | disclosed |
| WO-2017011444-A1 | METHODS AND COMPOSITIONS FOR TREATING B CELL CANCERS | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2017-01-19 | — | — | WO | disclosed |
| WO-2015168599-A1 | COMBINATION THERAPIES TARGETING MITOCHONDRIA FOR CANCER THERAPY | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2015-11-05 | — | — | WO | disclosed |
| WO-2015130922-A2 | SMALL MOLECULE HSP70 INHIBITORS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-09-03 | — | — | WO | disclosed |
| US-20110189125-A1 | Modulators of HSP70/DnaK Function and Methods of Use Thereof | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-08-04 | — | — | US | disclosed |
| US-20100330089-A1 | ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS | WYETH (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158146-A1 | HSP70 Inhibitors and Methods of Using Same | HSPA2, HSPBP1, HSP90AB1 | LMNA 4569/4885CYP1A2 3538/4885THRB 4619/4885 |
| US-20110189125-A1 | Modulators of HSP70/DnaK Function and Methods of Use Thereof | HSPBP1, HSPE1, HSP90B1 | LMNA 2610/4885CYP1A2 4765/4885THRB 3161/4885 |
| US-20230146903-A1 | CXCR5 Antagonists and Methods of Treating Diseases or Disorders Using Same | CXCR5, CXCR1, CXCR3 | LMNA 4726/4885CYP1A2 4671/4885THRB 2185/4885 |
| US-20170014434-A1 | Small Molecule HSP70 Inhibitors | HSPE1, HSPD1, DNAJA3 | LMNA 1665/4885CYP1A2 3034/4885THRB 2027/4885 |
| US-20220213014-A1 | CRYSTALLINE POLYMORPHS OF 1,6-DIBROMO-1,6-DIDEOXY-DULCITOL | TP53, BBC3, DDB1 | LMNA 919/4885CYP1A2 536/4885THRB 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.